converting enzyme (ACE) is identical with kininase II. Besides reducing the production of angiotensin II, inhibition of ACE potentiates the biological actions of endogenous kinins. In hypertension-induced left ventricular hypertrophy, potentiation of endogenous kinins contributes to the improvement of cardiac function and energy metabolism and to capillary proliferation effected by ACE inhibitors. In myocardial infarction (MI), the potentiation of kinins has been shown to be involved in the reduction of infarct size and improvement of cardiac function by ACE inhibition. The cardioprotective actions of ACE inhibition in MI seem to be, in part, mediated by the augmentation of myocardial blood flow, especially in the ischemic region of the heart.
Introduction
The renin angiotensin system is generally known to play a major pathophysiological role in the development of hypertension and cardiovascular diseases such as left ventricular hypertrophy (LVH), congestive heart failure and cardiac remodeling post myocardial infarction (MI).
The clinical success of angiotensin converting enzyme (ACE) inhibitors has proven the pathophysiological significance of the renin angiotensin system (RAS) in cardiovascular diseases. Experimental and clinical results obtained with the newly discovered angiotensin II (ANG II) receptor antagonists such as losartan, varsaltan, irbe sartan and candesartan underline the importance of the RAS. Although many of the actions of ACE inhibitors can be explained by the inhibition of ANG II production in circulating blood and various organs, the ACE in hibitor-induced potentiation of kinins may also contrib ute to the clinical benefits of these drugs. ACE is a metalloprotease with two homologous domains, i.e., two binding sites as active centers contain ing a zinc atom each (1) . ACE is also known to be identi cal with kininase II, a bradykinin (BK) degrading en zyme (2) . ACE converts the inactive decapeptide angio tensin I into the biologically active octapeptide ANG II by removing the dipeptide, His-Leu, from the C-termi nal end of the angiotensin I molecule. On the other hand, ACE inactivates BK by sequential removal of dipeptides Phe-Arg and Ser-Pro from the C-terminal end of the peptide. The inhibition of ACE potentiates the biological actions of BK as well as attenuates the actions of ANG II, allowing for the possibility that kinins contribute to the effects of ACE inhibitors. In the present short review, we will focus on the contribution of kinins to cardioprotec tive actions of ACE inhibitors in hypertension and after MI on the basis of our recent findings.
Biological action of kinins
Several kinins such as the nonapeptide 13K, the decapeptide Lys-BK (kallidin), the undecapeptides Met Lys-BK and Ile-Ser-BK (T-kinin), Met-T-kinin and T kinin-Leu have been identified in mammalian species (3). All kinins share the common amino acid sequence of BK (-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH) at the C terminal (4 6).
Kininogens, which belong to the a2-globulin fraction, are mainly synthesized in the liver. Three types of kinino gens exist in the rat, i.e., high and low-molecular weight kininogens and T-kininogen (7, 8) . Kininogens are cleaved by enzymes (kininogenases) such as plasma kal likrein in the liver and glandular or tissue kallikrein in exocrine glands or the kidney, resulting in the production of kinins (9) .
Kinins exert several biological actions. Intravenous in jection of BK produces a short lasting decrease in blood pressure via arterial vasodilation (10, 11) . The latter is due to the stimulation of nitric oxide as well as the prostacyclin production in the endothelium (12, 13) . In addition to vasodilation, several other biological actions of kinins have been demonstrated. Kinins are involved in nociception (14) as well as in inflammation and capillary permeability (15) . Kinins also mediate reactive hyperemia (16) and stimulate cellular glucose uptake (17) . In the kidney, kinins affect the renal vascular resistance and produce diuresis and natriuresis (18, 19) . Kinins exert their biological effects via the stimulation of kinin receptors. Two subtypes of kinin receptors, designated B1 and B2, have been characterized (20, 21) . The B1-receptor has a high affinity to kininase I metabo lites such as Des-Arg9-BK and Des-Arg10-kallidin, whereas the B2-receptor recognizes BK and kallidin. The B1-receptor is not present in normal tissues but is induced under certain pathophysiological conditions such as tis sue injury and stress. In contrast, B2-receptors mediate most of the biological actions of BK.
Kinin receptor antagonists have been widely used as tools to clarify the physiological and pathophysiological role of kinins. Icatibant (Hoe 140) is one of the potent and selective antagonists for the B2-receptor (22) (23) (24) .
Contribution of kinins to the cardioprotective actions of ACE inhibitors in hypertension
Arterial hypertension is known to be accompanied by an adaptative LVH. Cardiac hypertrophy can also be seen in well-trained athletes; however, the physiologically hypertrophied heart contracts forcefully with much less risk for cardiovascular events. Capillaries of physiologi cally hypertrophied hearts grow in proportion to the enlargement of myocytes (25) . On the other hand, hyper tension-induced LVH is a prominent cardiovascular risk factor closely related to ischemia, lethal arrhythmias and cardiac failure (26) . Adaptative LVH in hypertension is induced in order to overcome the chronically increased afterload imposed on the heart. In contrast to the phys iologically hypertrophied heart, the rate of capillary growth of the hypertension-induced hypertrophied heart does not keep pace with the increase in muscular mass (27) . The reduced capillary supply may eventually lead to cardiac ischemia followed by arrhythmias and cardiac failure. In addition, LVH is often accompanied by perivascular fibrosis of intramyocardial coronary arteries and by interstitial fibrosis (28, 29) . Clinical studies in patients with essential hypertension accompanied by LVH have shown that ACE inhibitors can regress LVH in addition to their antihypertensive effect (30) (31) (32) (33) . While part of the regressive effect of ACE inhibitors on LVH can be explained by blood pressure reduction, there is evidence for an additional mechanism in experimental models of hypertension.
Aortic banding between the renal arteries is known as an experimental model of renal hypertension in which LVH is induced by pressure overload to the heart. In rats with aortic banding, an antihypertensive dose of the ACE inhibitor ramipril prevented and regressed LVH, respec tively, whereas equipotent doses of the calcium antago nist nifedipine and the arterial vasodilator dihydralazine had no effect on LVH in spite of their antihypertensive actions (34) . Interestingly, a sub-antihypertensive dose of ramipril also prevented LVH, demonstrating that the ACE inhibitor exerted preventive effects of LVH in dependently of its antihypertensive actions in this model of hypertension.
When the ramipril treatment was begun prior to the establishment of LVH (just after the aortic constriction), the antihypertrophic effect was abolished by co-treatment with the B2-receptor antagonist, icatibant. On the other hand, co-treatment with icatibant was not able to reverse the antihypertrophic effect of ramipril when ramipril treatment was begun after the establishment of LVH (6 weeks after aortic constriction). Chronic infusion of BK at a dose that did not affect systemic blood pressure also prevented the development of LVH, whereas it had no regressive effect on LVH (35) . These findings indicate that potentiation of endogenous kinins contributed to the beneficial effect of ACE inhibitor on the development of LVH but was not involved in the regressive effect of the agent under these experimental conditions.
In spontaneous hypertensive rats (SHR) and stroke prone spontaneous hypertensive rat (SHRSP), an animal model for essential hypertension, antihypertensive doses of the ACE inhibitors ramipril, zabicipril and perindopril prevented LVH when treatment was begun before the de velopment of hypertension (36) (37) (38) (39) . Sub-antihyperten sive doses of these ACE inhibitors had no effect on LVH. Therefore, in these genetically hypertensive animals, the anti-hypertrophic effects of ACE inhibitors seem to be due to their antihypertensive actions, i.e., reduction of afterload imposed on the heart. In addition, co-treatment with icatibant did not affect the antihypertensive or anti hypertrophic actions of ACE inhibitors in SHR and SHRSP, suggesting that kinins do not contribute to the antihypertrophic effects of ACE inhibitors in rats with genetic hypertension. The discrepancy between findings from rats with ge netic hypertension, on one hand, and with aortic banding, on the other hand, could be explained by differences in the pathogenic mechanisms between these experimental models of hypertension. Rats with renal hypertension respond to ACE inhibition more drastically than rats with genetic hypertension because they are highly dependent on the RAS and appear to feature a compensatory stimu lation of the kinin system. In contrast, SHR or SHRSP seem to be dependent to a lesser degree on both hormonal systems (40, 41) .
However, we can not rule out the involvement of kinins in the beneficial effect of ACE inhibitor even in rats with genetic hypertension. For instance, Gohlke et al. (38, 39) demonstrated a contribution of kinins to the improve ment of cardiac function by ACE inhibitors in SHRSP. Chronic treatment with ramipril improved cardiac func tion, as demonstrated by increases in left ventricular pressure, dP/dt max and coronary flow. These effects of ramipril were accompanied by reduced activities of lac tate dehydrogenase and creatinine kinase in the venous effluent of the heart and by increased myocardial high energy phosphates and glycogen, whereas tissue lactate was reduced ( Table 1 ). The beneficial effects of ramipril were abolished by co-treatment with icatibant. These findings demonstrate that the potentiation of endogenous kinins contributed to the improvement of cardiac func tion by the ACE inhibitor in rats with genetic hyperten sion. The development of LVH in rats with genetic hypertension is associated with a diminished capillary density. Chronic, early-onset treatment with an anti hypertensive dose of ramipril and perindopril increased capillary density in the left ventricle (37, 42) . Even a sub antihypertensive dose of the ACE inhibitor ramipril im proved myocapillary density (37, 42) . The beneficial ac tion of ACE inhibition on capillary proliferation seems to be independent of the antihypertensive and antihyper trophic effects; however, the mechanism has not yet been fully clarified. It may be, in part, explained by the inhibi tory effect of ACE inhibitors on ANG II production, because ANG II inhibits the serum and basic fibroblast growth factor (bFGF)-stimulated proliferation of coro nary endothelial cells through the AT2-receptor (43, 44) . However, we can not rule out the involvement of kinins since B2-receptor blockade prevented the increase in myocapillary density induced by ACE inhibitor treat ment (42) . The perfusion of BK has been shown to im prove myocardial blood flow in the ischemic heart (45). ACE inhibitor-induced augmentation of coronary flow was abolished by icatibant (38, 39, 45) . Therefore, kinin mediated vasodilation and augmentation of myocardial blood flow may contribute to the capillary proliferation, because it has been shown that the mechanical shear stress on the surface of the endothelial cells following vasodila tion and increased blood flow was a trigger for capillary growth (46) . It could be considered that potentiation of endogenous kinins contributed to the capillary prolifera tive action of ACE inhibitor. Fig. 1 . Cardioprotective effects of ACE inhibitor, angiotensin II receptor antagonist and the combination of ACE inhibitor and B2 kinin receptor antagonist in myocardial infarction in rats. Upper and lower panels represent the effects of these agents on the infarct size and end-diastolic pressure (EDP), respectively. Moexipril and losartan were administered orally to rats at a dose of 10 mg/kg daily. Icatibant was co-administered with moexipril at a dose of 0.5 mg/kg (s.c.) daily. These treatments were begun 1 week prior to the left coronary artery ligation and were continued for 6 weeks. *P<0.05 vs control value.
Contribution of kinins to the cardioprotective actions of ACE inhibitors following myocardial infarction
ACE inhibitors have been advocated as therapeutic agents for patients with chronic heart failure after MI. In fact, clinical studies have provided evidence for the cardioprotective and mortality reducing effects of ACE inhibitors post MI (47) (48) (49) (50) (51) .
The mechanism of the cardioprotective and life-saving actions of ACE inhibitors post MI can be explained, in part, by their lowering effect on afterload imposed on the damaged heart, resulting in a decrease in energy consump tion of the myocardium. However, Martorana et al. (52) suggested other possibilities based on their observation that locally administered ramipril (intracoronary infu sion) significantly reduced infarct size in dogs without affecting systemic blood pressure. They also reported that the intracoronary administration of BK had similar cardioprotective effects as ramipril and that the B2-recep tor antagonist icatibant prevented the effects of the ACE inhibitor. Therefore, the beneficial effects of ACE inhibi tor in MI do not seem to be only due to the reduced after load imposed on the heart but may depend also on BK potentiation.
Recent investigations from our group give further support to the possibility that kinins contribute to the cardioprotective effect of ACE inhibitors following MI (53) . As shown in Fig. 1 , the ACE inhibitor moexipril reduced infarct size and prevented the increase in end diastolic pressure in rats with MI when the chronic treat ment for 6 weeks post MI was begun one week prior to coronary ligation. Co-treatment with the B2-receptor an tagonist icatibant abolished these effects of moexipril. In terestingly, the AT,-receptor antagonist losartan had no cardioprotective effects under these experimental condi tions (53) . In line with these findings, Hartman et al. (54) found that intracoronary infusion of ramipril, but not losartan, reduced infarct size when treatment was begun prior to the occlusion of the left coronary artery in rab bits. On the other hand, when treatment with ACE inhi bitor was begun 6 weeks after coronary ligation, i.e., when congestive heart failure had developed, moexipril had no significant effects on infarct size or end-diastolic pressure, whereas losartan improved cardiac function as demonstrated by a significant reduction of end-diastolic pressure (55) .
Based on these findings, one could speculate that in an earlier stage of MI, during the remodeling process of the damaged heart, the potentiation of endogenous kinins is closely related to cardioprotective effects of ACE inhibi tors as demonstrated by the reduced infarct size and prevention of the increase in end-diastolic pressure. On the other hand, in a later stage of MI, the stage of de velopment of congestive heart failure, the reduction of ANG II production gain more importance.
Ertl (56) reported that ACE inhibitor treatment reduced the area at risk and the infarct size more effec tively in dogs with coronary artery ligation. We measured tissue blood flow in the marginal zone of the area at risk 30 min before and after left coronary artery ligation in rats. In animals pretreated with ramipril, tissue blood flow in the marginal zone of the infarct area after the ligation was higher than that in non-treated animals. In addition, the infarct size 3 weeks after MI was found to be reduced even when the treatment was withdrawn after MI. Co-treatment with icatibant abolished these benefi cial effects of ramipril. Losartan had no significant effects on blood flow and infarct size (57) . These findings sug gested that the ACE inhibitor improved collateral myo cardial blood flow especially in the marginal zone of ischemia by potentiation of endogenous kinins. The mechanism have been responsible for the reduction of infarct size.
From these data, it appears that kinins contribute to the cardioprotective actions of ACE inhibitor especially in the acute ischemic phase of MI. Indeed in ischemic isolated working rat hearts submitted to reperfusion injury, perfusion with BK or ACE inhibitors improved cardiac function and coronary flow, reduced the release of lactate dehydrogenase and creatine kinase into the perfusate and preserved myocardial content of energy stores as demonstrated by maintained glycogen, ATP and creatine phosphate (58) . In addition, postischemic reper fusion arrhythmias were distinctly attenuated by per fusion with BK or ACE inhibitor at doses that had no cardiodynamic actions (59) . The effects of ACE inhibition were abolished by icatibant (45) . Thus, the potentiation of endogenous kinins seems to contribute to the cardioprotective effects of ACE inhibition in myocardial ischemia not only by the improvement of myocardial blood flow but also by the improvement of energy metabolism in the ischemic heart. 5. Contribution of kinins to the action of ACE inhibitors on myocardial remodeling As described above, myocardial remodeling is a conse quence of MI. Left ventricular remodeling after MI is as sociated with morphological changes such as increase in left ventricular mass, chamber dilation and compensatory hypertrophy of the non-infarcted myocardium. In an earlier stage of MI, necrosis, edema and vascular conges tion can be seen, and the left ventricle dilates as the result of expansion of the infarcted area by thinning and dila tion of the necrotic region. In necrotic tissue, a thin scar is formed and a collagen network protects against further expansion. The compensatory hypertrophy of the res idual viable myocardium takes place to overcome the decreased contractility of the damaged heart to maintain stroke volume. Even after the healing process is complet ed, the ventricular remodeling continues (60) . ACE ex pression was markedly increased in the repairing scar af ter 3 weeks of MI (61) . ACE was also expressed in macro phages and endothelial cells, but the enzyme could not be found in vascular smooth muscle cells, cardiomyocytes or fibroblasts (61) . These findings suggest that ACE is closely related to tissue repair and remodeling after MI.
ACE inhibitors have been shown to reduce cardiac mass and volume while maintaining cardiac output post MI (62) (63) (64) (65) . The mechanism of the anti-remodeling effect of ACE inhibitors is still controversial. A reduction of afterload on the heart may contribute to the effect of the ACE inhibitors; however, hydralazine had no effect on remodeling in spite of its antihypertensive effect (66) . AT,-receptor antagonist have been reported to attenuate the structural change in myocardium after MI (64, 67) . On the other hand, McDonald et al. (68) demonstrated that an AT,-receptor antagonist was ineffective in dogs with transmyocardial direct current shock, a model for myocardial necrosis. Furthermore, the B2 kinin receptor antagonist icatibant abolished the anti-remodeling effect of the ACE inhibitor (69) . Together, these findings allow for the possibility that kinins contribute to the anti remodeling effect of ACE inhibitors under certain condi tions.
Conclusion
We have given several examples for the contribution of kinins to the cardioprotective actions of ACE inhibitors in hypertension, LVH and post MI. The potentiation of endogenous kinins appears to contribute to the anti hypertrophic effect of ACE inhibitor, especially in the developmental stage of hypertension-induced LVH. Ki nins also contribute to the improvement of cardiac func tion and energy metabolism by ACE inhibitors in LVH. In the early stage of MI, the remodeling process of damaged heart, the potentiation of endogenous kinins appear to contribute to beneficial effects of ACE inhibi tors on infarct size and cardiac function, possibly by the augmentation of myocardial blood flow, especially in the ischemic region of the heart. Moreover, kinins can also contribute to the anti-remodeling effects of ACE inhibi tor, although the mechanism is still controversial. Further studies will be needed to clarify how cardiac kinins pro tect the heart in LVH and MI.
